Provided by Tiger Trade Technology Pte. Ltd.

CHINARES PHARMA

4.810
-0.075-1.54%
Volume:8.23M
Turnover:39.48M
Market Cap:30.22B
PE:6.41
High:4.930
Open:4.930
Low:4.755
Close:4.885
52wk High:6.336
52wk Low:4.211
Shares:6.28B
HK Float Shares:6.28B
Volume Ratio:1.51
T/O Rate:0.13%
Dividend:0.22
Dividend Rate:4.53%
EPS(LYR):0.751
ROE:8.96%
ROA:2.91%
PB:0.50
PE(LYR):6.41
PS:0.10

Loading ...

China Resources Pharmaceutical Group - Final Dividend of RMB0.122 per Share

THOMSON REUTERS
·
Mar 25

China Resources Pharmaceutical FY2025 profit attributable to shareholders rose 20.7% to RMB4.05 billion

Reuters
·
Mar 25

CR Sanjiu 2025 net profit attributable to shareholders rises 1.58% to RMB3.42 billion

Reuters
·
Mar 20

CR Boya Bio-pharmaceutical 2025 Profit Drops 71.61%; Revenue Rises 18.69%—Subsidiary of CHINARES PHARMA

Bulletin Express
·
Mar 20

China Resources Pharma Reports 71.61% Net Profit Decline for Boya Bio-Pharmaceutical in 2025

Stock News
·
Mar 20

China Resources Pharmaceutical - FY Revenue RMB2.06 Bln for Cr Boya Bio-Pharmaceutical

THOMSON REUTERS
·
Mar 20

CR Boya Bio-pharmaceutical revenue rises 18.69% to RMB2.06 billion in 2025

Reuters
·
Mar 20

Jiang Zhong Pharmaceutical's Profit Jumps 15% in 2025

MT Newswires Live
·
Mar 20

China Resources Pharma (03320.HK) Subsidiary Dong-E-E-Jiao Posts 2025 Net Profit of RMB 1.74 Billion, Up 11.66%

Bulletin Express
·
Mar 19

China Resources Pharmaceutical Group Ltd - FY Revenue for Dong-E-E-Jiao RMB6.70 Bln

THOMSON REUTERS
·
Mar 19

CR Pharma (03320) Subsidiary KPC Records 46% Profit Decline in FY 2025, Revenue Falls 22%, Announces RMB 0.18 Cash Dividend Per Share

Bulletin Express
·
Mar 19

BRIEF-China Resources Pharmaceutical Says KPC Pharmaceuticals Proposes Dividend Of Rmb1.80 per 10 Shares

Reuters
·
Mar 19

China Resources Pharmaceutical - Kpc Pharmaceuticals FY Revenue RMB6.58 Bln

THOMSON REUTERS
·
Mar 19

China Resources Pharmaceutical - Kpc Pharmaceuticals Proposed to Distribute Cash Dividend of RMB1.80 for Every 10 Shares

THOMSON REUTERS
·
Mar 19

CR Double-Crane net assets attributable to shareholders rise 11.78% to RMB11.63 billion in 2025

Reuters
·
Mar 19

China Resources Pharmaceutical (03320) Discloses FY2025 Results of Subsidiary Tasly Pharmaceutical: Revenue Down 3.08%, Core Net Profit Up 15.63%

Bulletin Express
·
Mar 19

CHINARES PHARMA (03320) Reports Tasly Pharmaceutical's 2025 Net Profit Attributable to Shareholders at RMB 1.105 Billion, Up 15.63%

Stock News
·
Mar 19

CR Sanjiu affiliate Tasly Pharmaceutical reports 2025 net profit of RMB1.1 billion, up 15.63%

Reuters
·
Mar 19

CHINARES PHARMA (03320): Subsidiary CR Jiangzhong Delivers 15.03% Profit Growth in FY 2025, Proposes RMB0.88 Dividend per Share

Bulletin Express
·
Mar 19

China Resources Pharmaceutical - FY Revenue of Cr Jiangzhong Pharmaceutical RMB4.22 Bln

THOMSON REUTERS
·
Mar 19